Recursion Pharmaceuticals (RXRX) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Taysha Gene Therapies (TSHA) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, losing 11.2% versus a loss of 41.2%. Over five years, TSHA leads with a -70.7% price change compared with -87.0% for RXRX. Recursion Pharmaceuticals is the larger company by market cap ($1.53 billion vs $1.21 billion), about 1.3 times the size.
Recursion Pharmaceuticals converts more of its revenue into profit, with a net margin of -863.4% versus -1115.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RXRX | TSHA |
|---|---|---|
| Share price | $2.45 | $3.72 |
| Market cap | $1.53B | $1.21B |
| 1-day change | -9.93% | -1.33% |
| YTD return | -40.10% | -32.36% |
| 1-year return | -41.25% | -11.22% |
| 5-year return | -87.04% | -70.69% |
| EPS (TTM) | $-0.86 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $74.68M | $9.77M |
| Revenue growth (YoY) | +26.92% | +17.28% |
| Net income (latest FY) | $-644.76M | $-109.00M |
| Gross margin | 4.99% | — |
| Operating margin | -867.87% | -1130.65% |
| Net margin | -863.35% | -1115.27% |
| 52-week high | $5.24 | $7.30 |
| 52-week low | $2.44 | $3.46 |
| Distance from 52-week high | -53.24% | -49.04% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +176.33% | +249.46% |
| Average volume | 24.47M | 3.59M |
| Shares outstanding | 622.76M | 326.05M |
| Employees | 600 | 99 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TSHA has outperformed RXRX by 30.0 percentage points over the past year.
- Recursion Pharmaceuticals is more profitable, keeping -863.4 cents of every revenue dollar as net income versus -1115.3 cents for Taysha Gene Therapies.
- Recursion Pharmaceuticals grew revenue faster in its latest fiscal year (+26.92% vs +17.28%).
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees
RXRX vs TSHA FAQ
Which is bigger, Recursion Pharmaceuticals or Taysha Gene Therapies?
Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $1.53B compared with $1.21B for Taysha Gene Therapies (TSHA).
Which stock has performed better over the past year, RXRX or TSHA?
TSHA returned -11.22% over the past 12 months, compared with -41.25% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Recursion Pharmaceuticals and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.